Emergent BioSolutions Inc. (EBS): Total Assets
$1.32B
As of 2025-12-31
$1.12B
As of 2026-06-30
-25.3%
3-year compound annual growth
-14.5%
5-year compound annual growth
+2.4%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.32B | -5.1% | 2026-02-27, Balance as of period end |
| 2024-12-31 | $1.39B | -23.8% | 2026-02-27, Balance as of period end |
| 2023-12-31 | $1.82B | -42.4% | 2025-03-04, Balance as of period end |
| 2022-12-31 | $3.17B | +7.1% | 2024-03-08, Balance as of period end |
| 2021-12-31 | $2.96B | +2.6% | 2023-12-11, Balance as of period end |
| 2020-12-31 | $2.88B | +23.9% | 2022-02-25, Balance as of period end |
| 2019-12-31 | $2.33B | +4.4% | 2021-02-19, Balance as of period end |
| 2018-12-31 | $2.23B | +108.3% | 2020-02-25, Balance as of period end |
| 2017-12-31 | $1.07B | +10.3% | 2019-02-22, Balance as of period end |
| 2016-12-31 | $970.11M | -6.5% | 2018-02-23, Balance as of period end |
| 2015-12-31 | $1.04B | +10.5% | 2017-02-28, Balance as of period end |
| 2014-12-31 | $938.69M | +49.8% | 2016-02-29, Balance as of period end |
| 2013-12-31 | $626.63M | +11.1% | 2016-02-29, Balance as of period end |
| 2012-12-31 | $564.23M | +3.2% | 2015-03-09, Balance as of period end |
| 2011-12-31 | $546.86M | +9.3% | 2014-03-10, Balance as of period end |
| 2010-12-31 | $500.32M | n/a | 2013-03-08, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $1.32B | -5.1% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $1.26B | -18.6% |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $836.65M | -0.5% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $1.63B | +3.3% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $1.45B | +6.2% |
| Collegium Pharmaceutical, Inc (COLL) | 2025-12-31 | $1.66B | -0.4% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $763.63M | +31.5% |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | $1.53B | +1.9% |
| Arrowhead Pharmaceuticals, Inc. (ARWR) | 2025-09-30 | $1.39B | +21.5% |
Compare EBS, PCRX, CORT, AMPH side by side · Screen every company in Pharmaceutical Preparations ↗